Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs

 
• By Ayisha Sharma

The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.  

The Omicron Variant Of Concern Has Over 30 Mutations • Source: Alamy

More from COVID-19

More from Scrip